Gefitinib as a first line therapy in a patient with non small cell lung cancer STRESZCZENIE

Abstract

A case report of a 65-year-old woman who received gefitinib as a first line therapy for adenocarcinoma of the lung between March 2013 and October 2014 at Oncology Centre M. Sklodowska-Curie Memorial Institute in Warsaw. The patient was diagnosed as clinical stage IV (both lung metastasis). The treatment was well tolerated. The clinical and radiological benefits of EGFR-tyrosine kinase inhibitor (TKI) have been observed in the above patient with EGFR mutation.